Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Adverum Biotechnologies has hired Thomas Kochy to the role of vice president of commercial and program strategy. Kochy previously served as a strategy consultant in ocular disease areas and was also regional sales director for Genentech.
Roberto Iacone, former entrepreneur in residence at Versant Ventures, has been named CEO of Alentis Therapeutics.
Arcutis Biotherapeutics has recruited Patrick Burnett to join the company as its newest chief medical officer. Burnett was tapped from Verrica Pharmaceuticals, where he served as chief medical officer.
Libbie Mansell has been named senior vice president of regulatory affairs at AskBio. Previously, Mansell was managing director of White Oak BioPharma Solutions.
Jae Kim has been named chief medical officer of Avidity Biosciences. Prior to joining Avidity, Kim was clinical research head at Alnylam Pharmaceuticals.
Chiesi Group has appointed Thomas Eichholtz to head of global research and development. Eichholtz was recently head of external research and development at Mundipharma.
Tanya Moreno has been named vice president of development at Cradle Genomics. Formerly, Moreno was chief science officer at Wamberg Genomic Advisors. Cradle also named Sue Gross chief medical officer of the company. Gross currently serves as president and CEO of the ObG Project.
Bryan Laffitte, former vice president of biology at Inception Therapeutics, will now serve as vice president of biology at DTx Pharma.
Elligo Health Research
Elligo Health Research has named Michael Gibertini chief development officer of the company. Previously, Gibertini was president of clinical development at Syneos Health.
Engrail Therapeutics has promoted Kimberly Vanover to the role of chief scientific officer and Eve Taylor to the position of vice president of clinical development. Vanover was formerly senior vice president of early-stage clinical development and translational medicine, and Taylor was senior director of clinical development.
Tim Miller has been named CEO of Forge Biologics. Miller was most recently the president and chief scientific officer at Abeona Therapeutics.
Gain Therapeutics has found its new CEO in Eric Richman, former president and CEO of PharmAthene.
Michele Korfin has been appointed to the role of chief operating and chief commercial officer at Gamida Cell. Korfin was previously the chief operating officer at TYME Technologies.
Generation Bio has appointed Matthew Norkunas to the role of chief financial officer. Norkunas was recently the chief financial officer at SomaLogic.
Gracell Biotechnologies has named Martina Sersch the company’s new chief medical officer. Most recently, Sersch was chief medical officer at Mustang Bio. Kevin Xie, former president of Fosun Healthcare Holdings, has been named chief financial officer of Gracell.
Ivan Yifei Zhu has been appointed to the role of chief commercial officer of biotech company I-Mab. Zhu joins I-Mab from Qilu Pharmaceutical Group, where he served as vice president and general manager of sales.
Barbara Kosacz, former international head of Cooley LLP’s Life Sciences Practice, has been named chief operating officer and general counsel of Kronos Bio.
La Jolla Pharmaceutical Company
Larry Edwards has taken the helm at La Jolla Pharmaceutical, where he joins the company as its new president and CEO. Edwards was recently the CEO of Tetraphase Pharmaceuticals.
Amit Aggarwal has been appointed to the role of medical director at LEO Pharma. Most recently, Aggarwal served as director of medical affairs at Bayer.
Andrew Joe has joined Merus, a Netherlands-based biotech, as its newest chief medical officer. He was previously a vice president of oncology development at Sanofi.
Dagmar Rosa-Bjorkeson has been named chief operating officer of Mesoblast Limited. Most recently, Rosa-Bjorkeson was executive vice president and president of biosimilars at Baxalta.
NeuBase Therapeutics has named William Mann the company’s newest chief operating officer. Mann was most recently president and CEO of Helsinn Therapeutics.
Parker Institute for Cancer Immunotherapy
John Connolly has joined Parker Institute for Cancer Immunotherapy as its chief scientific officer. Prior to this role, Connolly was chief scientific officer of Tessa Therapeutics.
Salarius Pharmaceuticals has named Nadeem Mirza as senior vice president of clinical development. Mirza was previously chief medical advisor at TRIGR Therapeutics.
Alan Buckler has been named chief scientific officer of Triplet Therapeutics. Buckler recently served as chief scientific officer of Scholar Rock.
Erin Smith is the new senior vice president of government affairs and public policy at Twist Bioscience. Smith previously led a government affairs program at Gilead Sciences.
Gary Goldenberg is stepping down from the board of directors at Verrica Pharmaceuticals to become the company’s new chief medical officer. Verrica also named Brad Catalone to head of drug development. Catalone was previously the chief science officer at TSO3 Corporation.
Mark McCamish, who most recently served as president and CEO of Forty Seven, has joined Viracta Therapeutics as a strategic adviser.
Davide Molho, who was formerly the CEO of Evolution Research Group, joins Viroclinics Biosciences as the company’s newest CEO.
Windtree Therapeutics has named Pratap Paruchuru executive director of clinical development, Catherine Kacprzycki director of clinical operations and Tracy Rarick head of operations and program management. Most recently, Paruchuru was senior medical director of critical care at Novartis, Kacprzycki was associate director of clinical operations at Endo Pharmaceuticals and Rarick was director of program management at Boston Scientific. John Hamill has also been tapped by Windtree to serve as its new senior vice president and chief financial officer.